Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Zinc finger protein 215 (ZNF215) is a member of the large family of zinc finger transcription factors, characterized by the presence of multiple zinc finger domains that enable DNA binding and transcriptional regulation[1]. ZNF215 contains an N-terminal SCAN domain, a Kruppel-associated box A (KRABA) domain, and four C-terminal C2H2-type zinc finger domains[1]. It is imprinted in a tissue-specific manner with preferential expression in the testis. ZNF215 is encoded in the Beckwith-Wiedemann syndrome chromosome region-2 (BWSCR2) on chromosome 11p15 and is implicated in the etiology of Beckwith-Wiedemann syndrome, a growth disorder[1]. As a zinc finger protein, ZNF215 likely participates in gene regulatory functions, but it is not currently established as a direct therapeutic target, nor are specific drugs known to interact with it[1][4][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Zinc finger protein 215 (ZNF215).